Select basic information for advanced search
| Free word |
|---|
Effectiveness of Natalizumab in Japanese Patients with Multiple Sclerosis According to Background Factors: Findings from Second Report of an Interim Analysis of the Natalizumab Post-marketing Surveillance
About YOKOYAMA KAZUMASA
About 順天堂大 医 脳神経内科
About SATO RYUSUKE
About バイオジェン・ジャパン
About MAKIOKA HARUKI
About バイオジェン・ジャパン
About IIZUKA YUKIHIKO
About バイオジェン・ジャパン
About HASE MASAKAZU
About バイオジェン・ジャパン
About LING Yan
About バイオジェン・ジャパン
About TORII SHIN'ICHI
About バイオジェン・ジャパン
About SAIDA TAKAHIKO
About 京都保健会 京都民医連中央病院
About SAIDA TAKAHIKO
About 関西多発性硬化症セ
Material：
Volume： 55 Issue： 6 Page： 449-456 Publication year： Jun. 28, 2018
JST Material Number： Z0942A ISSN： 0037-380X Document type： Article
Article type： 原著論文 Country of issue： Japan (JPN) Language： JAPANESE (JA)
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
About factor
Semi thesaurus term：
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
About natalizumab
Please login to MyJ-GLOBAL to see full information. You also need to select "Display abstract, etc. of medical articles" in your MyJ-GLOBAL account page in order to see abstracts, etc. of medical articles.
Category name(code) classified by JST.
About Clinical application of immunotherapeutic agents and blood preparations
- Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
- Havrdova E, Galetta S, Hutchinson M, et al: Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-60.
- Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
- Butzkueven H, Kappos L, Pellegrini F, et al; TYSABRI Observational Program (TOP) Investigators: Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190-7.
- Saida T, Kira JI, Kishida S, et al; Natalizumab Trial Principal Investigators : Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord 2017; 11: 25-31.
Keywords automatically extracted from the title.
About 背景因子
About ナタリズマブ
About 日本人
About 多発性硬化症
About 有効性
About 使用成績調査
About 中間解析
Return to Previous Page
